Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer based on data showing 33% response rate and 27-month median survival. The company is launching a Phase 2 study and recently completed reincorporation from Canada to Nevada. This marks the second Fast Track Designation for pelareorep in gastrointestinal cancers.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median overall survival of 27 months versus 11.2 months with standard treatment.
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant metastatic colorectal cancer, driving shares up 19.7%.
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07554807 |
A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies |
NOT_YET_RECRUITING | PHASE3 |
| NCT07539311 |
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers |
RECRUITING | PHASE2 |
| NCT07529808 |
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07406269 |
Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery |
NOT_YET_RECRUITING | NA |
| NCT07272538 |
Predicting Chemotherapy Toxicity Using FRAIL and FIND in Older Adults With Gastrointestinal Cancers |
COMPLETED | |
| NCT07184047 |
Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers |
COMPLETED | |
| NCT07180251 |
Impact of Glycemic Variability on People With Gastrointestinal Cancer and Diabetes After Surgery |
ACTIVE_NOT_RECRUITING | NA |
| NCT07173244 |
A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors |
NOT_YET_RECRUITING | |
| NCT07098871 |
Predictive Value of Preoperative Rectus and Diaphragm Muscle Thickness for Postoperative Complications in Gastrointestinal Cancer Surgery |
COMPLETED | |
| NCT07039526 |
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. |
RECRUITING | PHASE2 |
